Here is a list of realistic events that will make the stock go higher.
1. Milestone payment
2. EU approval or any other country
3. Technosphere partnership announced
4. stellar script #'s
it is really the last two that can have a lasting impact.
i suck, totally slipped while I was trying t0 give u a thumbs up with my wine in the other hand. Perhaps it was one glass too many. translation; is one thumbs down was to be a thumbs up.
the other 2 lines will be approved at this point as well
in this case, I think what was presented as the tail ( Afrezza), will wag the dog (toujeo).
none of you have anything to worry about. these investments are small time. Now 1million shares is really something.
I have noticed the block selling events. They come immediately after a price increase. It also seems to point more shares sold for less of a drop. Perhaps an attempt to wear swing trader out.
I understand this sounds like a gross generalizing, pumping statement. However, I do believe that the vast majority of all actual investors are holding and the traders are here doing their thing. Short are try to keep from losing billions.
I have a huge amount of options in Jan 16 $3 calls. I plan to fully execute and hold the physical shares. How amy other investors will do the same. This creates a great deal of forced buying. Both now and in the next year. The outstanding options are a huge number from now to Jan 16
MNKD, will be a licensing revenue based company. They will sell each developed produce off and retain a liscensing agreement.
I have tried to tell other of this and the nature of the partnership. SNY cannot just cut and run. They are obligated to pay MNKD every milestone providing MNKD completes the milestones.
Keep in mind the sale are prearranged in the timeframe of 6 months prior. If I was thinking back then of selling shares I would have arranged to sell them after approval, partnership and around the time of the expected launch. Surely any one would have thought the price of stock could be in the $20's by now. But alas it is not the case.
SNY cannot cut and run. Should they decide to abandon the partnership now they will pay all milestone payment and development costs. This has been glossed over but it is in fact the case. Should MNKD fail to deliver on their end is the only was SNY can have an early termination without these costs. Partnerships have many binding agreements and many costs associated with these agreements and costs with not fulfilling one s commitment. This is the nature of business.
So here we are today. An increase of short interest because of the belief of failure of a product? Not likely. Concerns for cancer? Insane.
The case studies involved over 6000 human patients for over 3 years with an extremely high adherance percentage. There was NO cancer in any test subject. Two patients, one a smoker, had an observed abnormality, that was proven to be statically not significant. Still they discontinued the case study. One later resumed and had no further issues or findings of the trace cell abnormality.
Yet we are thown doubt and misleading information that implies a terrible health risk.